Phathom Pharmaceuticals (PHAT) Revenue & Revenue Breakdown
Phathom Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$682.00K
Latest Revenue (Q)
$16.35M
Phathom Pharmaceuticals Revenue by Period
Phathom Pharmaceuticals Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $682.00K | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | - |
Phathom Pharmaceuticals Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $16.35M | 123.27% |
2024-06-30 | $7.32M | 283.05% |
2024-03-31 | $1.91M | 180.35% |
2023-12-31 | $682.00K | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | - |
Phathom Pharmaceuticals Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
AMLX | Amylyx Pharmaceuticals | $380.79M | $416.00K |
KNSA | Kiniksa Pharmaceuticals | $270.26M | $112.21M |
BPMC | Blueprint Medicines | $249.38M | $128.18M |
LYRA | Lyra Therapeutics | $1.56M | $195.00K |
PHAT | Phathom Pharmaceuticals | $682.00K | $16.35M |
CGEM | Cullinan Oncology | - | - |
GPCR | Structure Therapeutics | - | - |
XFOR | X4 Pharmaceuticals | - | $560.00K |
CNSP | CNS Pharmaceuticals | - | - |
DAWN | Day One Biopharmaceuticals | - | $20.07M |
ABOS | Acumen Pharmaceuticals | - | - |
INZY | Inozyme Pharma | - | - |
TERN | Terns Pharmaceuticals | - | - |
IMMX | Immix Biopharma | - | - |
HEPA | Hepion Pharmaceuticals | - | - |